Cyrcadia, Inc. Prepares for iTBra™ Product Launch and Expands Strategic Operations to Asia

Cyrcadia, Inc.(CI) announced this week a strategic expansion to accelerate operations and market launch into Asia for early breast cancer monitoring. CI has entered into a License and Cooperation Agreement Cyrcadia Asia, Ltd. (CA), a newly formed company in Hong Kong which will serve as the base for the Asia market launch of CI’s proprietary iTBraTM technology expected to commence in late 2017 or early 2018 under the global CI brand of Cyrcadia Health. Under the License and Cooperation Agreement, Cyrcadia Asia has exclusive marketing rights to the iTBra technology and products in Asia. CA will assume and fund certain further product development and other activities with respect to the iTBra technology and products for the benefit of both CI and CA. The License and Cooperation Agreement also provides for certain other financial terms between the two parties intended to enable the launch of the technology and products in Asia. CI retains exclusive marketing rights to the United States, Mexico and Canada, with the marketing strategy for the iTBra technology and products in other countries to be further discussed by the parties. Having obtained U.S. FDA 510(k) Class II approval for its iTBra technology, CI has conducted clinical trials in the U.S. with its newly developed scalable product, which demonstrates greatly improved outcomes, beyond historical product results. CI’s predictive analytic artificial intelligence (AI) based technology now demonstrates 80%+ accuracy with a two-hour wear when compared with the original trials which required 48-hour wear and achieved 74% accuracy. CI and CA expect this greatly improved performance to support the use of the 510(k) approval to launch the technology and products...

Sports Business Advisor Mandy Antoniacci Joins Cyrcadia Health

CYRCADIA HEALTH EXPANDS ADVISORY BOARD WITH NATIONALLY RECOGNIZED AUTHOR AND SPORTS BUSINESS ADVISOR MANDY ANTONIACCI Magazine Columnist, Sports Business Advisor and Advocate for Social Change Fills Key Position for Cyrcadia Reno, Nev. – June 2, 2016 – Cyrcadia Health, awarded the 2016 Gold Edison Award as Top Healthcare Wearable for its early breast cancer screening technology, is pleased to announce the addition of Mandy Antoniacci to serve as sports business advisor and women’s health advocate for Cyrcadia. As an in-demand speaker and nationally recognized author whose published works have been featured in Inc., Business Insider, Huffington Post, Yahoo Sports and Yahoo Finance, Antoniacci fuses her extensive marketing and advertising experience in the fields of sports, technology and health and wellness to advocate social change in business. “Is a great honor to have Mandy fill such a key position in her business advisory role,” said Rob Royea, president of Cyrcadia. “Her success in both business and in public communications within professional sports, as well as her passion to serve the underserved, will help to accelerate our message about the empowerment of women taking control over their individual personal health knowledge. Mandy’s personal understanding of the impact of breast cancer brings a unique ownership to our cause, which will help in her ability to passionately spread our key message to all women, medical professionals and financial and strategic supporters. Antoniacci is also an advocate for women in her work as a Leadership Committee Member for the nonprofit Futures Without Violence, where she advises on policy and education for domestic violence prevention in conjunction with the National Football League and Major League Baseball.  In her role...

“‘iTBra’ Could Be the Key to Early Breast Cancer Detection”

Cyrcadia’s technology was recently featured and Columbus, Ohio’s WBNS-TV10, notifying the viewing public of the expansion of our clinical trials at The Ohio State University.  We are pleased to have Dr. William Farrar’s support in this endeavor.  Please have a look. ‘iTBra’ could be the key to early breast cancer detection....

Cyrcadia Health Takes Home Gold 2016 Edison Award for Top Health and Wellness Wearable

Reno, Nev. (PRWEB) April 27, 2016 — Cyrcadia, Inc. was recently awarded the gold level citation for Health and Wellness, Wearable and Sensors category from the prestigious Edison Organization presented last week at the annual gala in New York. The company’s breakthrough technology is designed to enable early breast cancer detection through use of a wearable device, the iTBra.™ The technology measures specific circadian biomarkers, which can be early indicators of breast cancer cell infusion. “Not only did Cyrcadia win, but the company beat hundreds of other innovators and dozens in this category to achieve this designation,” said Jason Starbird, CEO, Aebli Group/ Edison. “One in eight women in the U.S. are diagnosed with breast cancer annually and approximately 500,000 women die worldwide from the disease each year, many due to lack of early detection. The Cyrcadia technology may become a substantial game changer.” Cyrcadia’s wearable, smart phone-enabled iTBra technology, uses a comfortable data collection device placed under a bra to collect from two to twelve hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a Cyrcadia-patented process to identify abnormalities at the earliest stages of cellular change over time. The results collected from the technology are transferred through a smart device to a global cancer library, where advanced analytical analysis occurs. The results then are communicated back to the patient and physician. “We are honored to be receiving this highly regarded award,” said Rob Royea, president of Cyrcadia. “There are numerous and exciting technologies being developed in the healthcare field, which makes the selection of Cyrcadia as the...

The human element of IoE changing the way breast cancer is detected.

Vatsun Thirapatarapong November 3, 2015 8:47 am In Thailand, breast cancer is the number-one cancer killing women, averaging seven women dying per week. More than 19 million Thai women are now in risk of having breast cancer. Such statistics on the occurrence of breast cancer are terrifying, but incredible strides across all forms of cancer are taking place. In many cases, they come in the form of early detection through ground-breaking technology and the Internet of Everything (IOE) Read more here:...

Cyrcadia, Inc. Collaborates With the Canary Foundation for Early Breast Cancer Research

Reno, Nev. (PRWEB)September 22, 2015 via http://www.prweb.com/releases/2015/09/prweb12974574.htm Cyrcadia Health and the Canary Foundation announced their intention to enter into collaborative research on improved early cancer detection screening through the use of Cyrcadia’s wearable devices. Through funding support from the Canary Foundation, Cyrcadia has established a multi-site trial, beginning at a leading Bay Area cancer hospital with near term expansion to the Stefanie Spielman Comprehensive Breast Foundation at The Ohio State University. This research will involve a 173 patient study focused on early breast cancer health screening. “We are excited that the Canary Foundation has taken an interest in our personalized health screening technology,” said Rob Royea, president of Cyrcadia, Inc.    “The potential of collaboration with the only foundation in the world, which over the past 10 years has focused solely on early cancer detection, is highly prestigious. Working together on early biomarker identification for multiple states of cancer will be of significant benefit to our research. Our ability to correlate our findings with those biomarkers which are early indicators of breast cancer infusion is invaluable and could lead to additional applications for our wearable products.” One in eight women in the U.S. alone are diagnosed with breast cancer annually. Approximately 500,000 die worldwide from the disease each year, many due to lack of early detection. The company’s wearable, smartphone enabled technology, called the iTBraTM, uses a comfortable data collection device placed under a bra to collect from two to 12 hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of...

Cyrcadia, Inc. Announces ClinicalTrials.gov Listing for Its Entry into Clinical Trials for Wearable Breast Cancer Detection Device

Reno, Nev. Aug. 11, 2015 — Cyrcadia, Inc. (“Company”) announces its clinical trial listing on ClinicalTrials.gov for its wearable breast cancer early detection device at El Camino Hospital, in Mountain View, California and upcoming additional clinical study sites. ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, currently holding registrations from over 130,000 trials from more than 170 countries in the world. “We are enthused that we have initiated the El Camino Hospital trial in Mt. View, CA and have now finalized the ClinicalTrials.gov registry. We look forward to the additions of The James Cancer Hospital at The Ohio State University and the Canary Center at Stanford’s upcoming inclusion into our early breast cancer screening trials,” says Rob Royea, President of Cyrcadia, Inc. For those interested in learning more about the Cyrcadia clinical studies, ClinicalTrials.gov is the registry to use including all details about the study and its status. It is the only location where Cyrcadia will divulge information about the studies and will update the registry from time to time. All information desired about the clinical studies can be obtained there and will not otherwise be divulged by Cyrcadia, its staff or other related parties. All details about the study including descriptions, eligibility and contacts can be obtained there. Please follow this link: ClinicalTrials.gov/Cyrcadia or go to the clinicaltrials.gov website using the identifier NCT02511301 to learn more and follow progress of the study as it is reported. Utilizing its previous FDA cleared device as a...